Physician profile
Fu Fu He
NPI 1386601557
$101,227.61
in general payments reported to CMS, 2019-2025
63 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $4,850 · 2021: $13K · 2022: $16K · 2023: $13K · 2024: $17K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $25K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Education: $162 · Travel and Lodging: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $24,845.41 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,220.00 |
| Education | $162.21 |
| Travel and Lodging | $112.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $53,695.95 | 2019-2025 | Vemlidy, Livdelzi |
| Astrazeneca Pharmaceuticals LP | $5,942.64 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,263.21 | 2019-2025 | Jardiance, Ofev, Spiriva Respimat |
| Glaxosmithkline, LLC. | $5,066.48 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $4,405.28 | 2019-2025 | |
| Amgen INC. | $4,075.22 | 2019-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $3,350.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $2,163.51 | 2019-2025 | Jardiance, Emgality, Mounjaro |
| Amarin Pharma, INC. | $1,314.20 | 2019-2023 | |
| Pfizer INC. | $1,150.75 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,067.62 | 2019-2022 | |
| Insmed, INC. | $1,063.79 | 2019-2025 | Brinsupri, Arikayce |
| Bayer Healthcare Pharmaceuticals INC. | $997.59 | 2021-2025 | |
| Esperion Therapeutics, INC. | $774.34 | 2020-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $714.47 | 2019-2025 | Trulance, Xifaxan |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fu Fu He listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.